3C-like proteinase from SARS coronavirus catalyzes substrate hydrolysis by a general base mechanism
- PMID: 15078103
- DOI: 10.1021/bi036022q
3C-like proteinase from SARS coronavirus catalyzes substrate hydrolysis by a general base mechanism
Abstract
SARS 3C-like proteinase has been proposed to be a key enzyme for drug design against SARS. Lack of a suitable assay has been a major hindrance for enzyme kinetic studies and a large-scale inhibitor screen for SARS 3CL proteinase. Since SARS 3CL proteinase belongs to the cysteine protease family (family C3 in clan CB) with a chymotrypsin fold, it is important to understand the catalytic mechanism of SARS 3CL proteinase to determine whether the proteolysis proceeds through a general base catalysis mechanism like chymotrypsin or an ion pair mechanism like papain. We have established a continuous colorimetric assay for SARS 3CL proteinase and applied it to study the enzyme catalytic mechanism. The proposed catalytic residues His41 and Cys145 were confirmed to be critical for catalysis by mutating to Ala, while the Cys145 to Ser mutation resulted in an active enzyme with a 40-fold lower activity. From the pH dependency of catalytic activity, the pK(a)'s for His41 and Cys145 in the wild-type enzyme were estimated to be 6.38 and 8.34, while the pK(a)'s for His41 and Ser145 in the C145S mutant were estimated to be 6.15 and 9.09, respectively. The C145S mutant has a normal isotope effect in D(2)O for general base catalysis, that is, reacts slower in D(2)O, while the wild-type enzyme shows an inverse isotope effect which may come from the lower activation enthalpy. The pK(a) values measured for the active site residues and the activity of the C145S mutant are consistent with a general base catalysis mechanism and cannot be explained by a thiolate-imidazolium ion pair model.
Similar articles
-
Enzymatic activity characterization of SARS coronavirus 3C-like protease by fluorescence resonance energy transfer technique.Acta Pharmacol Sin. 2005 Jan;26(1):99-106. doi: 10.1111/j.1745-7254.2005.00010.x. Acta Pharmacol Sin. 2005. PMID: 15659121 Free PMC article.
-
Steady-state and pre-steady-state kinetic evaluation of severe acute respiratory syndrome coronavirus (SARS-CoV) 3CLpro cysteine protease: development of an ion-pair model for catalysis.Biochemistry. 2008 Feb 26;47(8):2617-30. doi: 10.1021/bi702107v. Epub 2008 Feb 1. Biochemistry. 2008. PMID: 18237196
-
A mechanistic view of enzyme inhibition and peptide hydrolysis in the active site of the SARS-CoV 3C-like peptidase.J Mol Biol. 2007 Aug 24;371(4):1060-74. doi: 10.1016/j.jmb.2007.06.001. Epub 2007 Jun 8. J Mol Biol. 2007. PMID: 17599357 Free PMC article.
-
Quaternary structure, substrate selectivity and inhibitor design for SARS 3C-like proteinase.Curr Pharm Des. 2006;12(35):4555-64. doi: 10.2174/138161206779010396. Curr Pharm Des. 2006. PMID: 17168761 Review.
-
The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds.Antiviral Res. 2015 Mar;115:21-38. doi: 10.1016/j.antiviral.2014.12.015. Epub 2014 Dec 29. Antiviral Res. 2015. PMID: 25554382 Free PMC article. Review.
Cited by
-
Functional map of SARS-CoV-2 3CL protease reveals tolerant and immutable sites.Cell Host Microbe. 2022 Oct 12;30(10):1354-1362.e6. doi: 10.1016/j.chom.2022.08.003. Epub 2022 Aug 11. Cell Host Microbe. 2022. PMID: 36029764 Free PMC article.
-
Identification of potential drug candidates to combat COVID-19: a structural study using the main protease (mpro) of SARS-CoV-2.J Biomol Struct Dyn. 2021 Oct;39(17):6649-6659. doi: 10.1080/07391102.2020.1798286. Epub 2020 Aug 3. J Biomol Struct Dyn. 2021. PMID: 32741313 Free PMC article.
-
Molecular dynamics simulation approach for discovering potential inhibitors against SARS-CoV-2: A structural review.J Mol Liq. 2022 May 15;354:118901. doi: 10.1016/j.molliq.2022.118901. Epub 2022 Mar 9. J Mol Liq. 2022. PMID: 35309259 Free PMC article. Review.
-
Liberation of SARS-CoV main protease from the viral polyprotein: N-terminal autocleavage does not depend on the mature dimerization mode.Protein Cell. 2010 Jan;1(1):59-74. doi: 10.1007/s13238-010-0011-4. Epub 2010 Feb 7. Protein Cell. 2010. PMID: 21203998 Free PMC article.
-
Discovery of Di- and Trihaloacetamides as Covalent SARS-CoV-2 Main Protease Inhibitors with High Target Specificity.J Am Chem Soc. 2021 Dec 15;143(49):20697-20709. doi: 10.1021/jacs.1c08060. Epub 2021 Dec 3. J Am Chem Soc. 2021. PMID: 34860011 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous